J Korean Endocr Soc.  2007 Feb;22(1):8-10. 10.3803/jkes.2007.22.1.8.

Aldosterone as a Cardiovascular Risk Factor

• Yoo SJ

• KMID: 2178236
• DOI: http://doi.org/10.3803/jkes.2007.22.1.8

Abstract

No abstract available.

MeSH Terms

Aldosterone*
Risk Factors*
Aldosterone

Reference

1. Conlin PR, Dluhy RG, Williams GH. Schrier RW, editor. Disorders of the renin angiotensin-aldosterone system. Renal and Electrolyte Disorders. 1997. 5th ed. Boston: Little Brown;349–392.

2. Conn JW. Presidential address: Part I. Painting background. Park II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955. 45:3–17.

3. Chen SY, Bhargava A, Mastroberardino L, Meijer OC, Wang J, Buse P, Firestone GL, Verrey F, Pearce D. Epithelial sodium channel regulated by aldosterone induced protein sgk. Proc Natl Acad Sci USA. 1999. 96:2514–2519.

4. Naray-Fejes-Toth A, Canessa C, Cleaveland ES, Aldrich G, Fejes-Toth G. sgk is an aldosterone-induced kinase in the renal collecting duct. J Biol Chem. 1999. 274:16973–16978.

5. Bhargava A, Fullerton MJ, Myles K, Purdy TM, Funder JW, Pearce D, Cole TJ. The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology. 2001. 142:1587–1594.

6. Christ M, Klauss V, Pliml W, Theisen K, Wehling M. Volumes and Na/Hantiporter activity of lymphocytes in patients with congestive heart failure. Clin Investig. 1994. 72:985–991.

7. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW. Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ Res. 1995. 76:973–979.

8. Gekle M, Silbernagl S, Wunsch S. Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells. J Physiol (Lond). 1998. 511:255–263.

9. Benitah JP, Vassort G. Androsterone upregulates Ca2+ current in adult rat cardiomyocytes. Circ Res. 1999. 85:1139–1145.

10. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension. 1997. 29:723–727.

11. Campbell SE, Diaz-Arias AA, Weber KT. Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press. 1992. 1:149–156.

12. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997. 95:1471–1478.

13. Torres VE, Young WF Jr, Offord KP, Hattery RR. Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med. 1990. 322:345–351.

14. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994. 121:877–885.

15. Hypokalemia, aldosteronism, and renal cysts (letter). N Engl J Med. 1990. 323:129–131.

16. Kim SY. Renin-angiotensin-aldosterone system and cardiovascular diseases. J Kor Endocrinol Soc. 2004. 19:551–572.

17. Park JR, Kim DJ, Yang SJ, Kim SH, Park SY, Yoo HJ, Lee YJ, Kim HY, Ryu OH, Lee KW, Seo JA, Kim SG, Choi KM, Baik SH, Choi DS. Comparison of Target Organ Damages between Primary Aldosteronism and Essential Hypertension. J Kor Endocrinol Soc. 2007. 22:11.

18. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the right and left ventricles in experimental hypertension. Circ Res. 1990. 67:1355–1364.

19. Young M, Head G, Funder JW. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995. 269:E657–E662.

20. Schunkert H, Hense HW, Muscholl M, Luchner A, Kurzinger S, Danser AH, Riegger GA. Associations between circulating components of the renin-angiotensin -aldosterone system and left ventricular mass. Heart. 1997. 77:24–31.

21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999. 341:709–717.

22. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000. 85:336–344.

23. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000. 141:3871–3878.

24. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplereonone: comparison with low sodium diet or potassium loading. Hypertension. 2002. 39:614–618.